



BEYOND THE SLIDES 2015  
1<sup>st</sup> UDINE ECMO WORKSHOP

DECEMBER 18-19, 2015

ECMO in different scenarios

# ECMO FOR SEPTIC SHOCK

Giovanni Cianchi

SODc Cure Intensive per il Trauma e Supporti Extracorporei.  
Az. Ospedaliero Universitaria Careggi-Firenze


# ECMO FOR SEPTIC SHOCK???

What do I know?

...I don't know a damn!



# Careggi ECMO Center numbers



| Mortality  |     |
|------------|-----|
| ECMO SS    | 44% |
| ECMO no-SS | 48% |

# ECMO FOR SEPTIC SHOCK


What do others know?

...not too much!



# Definite recommendation in pediatric and newborn Septic Shock


American College of Critical Care Medicine  
Clinical Guidelines for Hemodynamic Support  
of Neonates and Children with Septic Shock



# Mortality in PSS is related to the number of organ dysfunction not to age.


| Characteristic    | ECMO alone (N = 1358) |              |
|-------------------|-----------------------|--------------|
|                   | Prevalence            | Mortality    |
| Age               |                       |              |
| <1 year           | 661 (48.7 %)          | 344 (52.0 %) |
| 1-4 years         | 319 (23.5 %)          | 130 (40.8 %) |
| 5-9 years         | 126 (9.3 %)           | 57 (45.2 %)  |
| 10-18 years       | 252 (18.6 %)          | 118 (46.8 %) |
| Organ dysfunction |                       |              |
| 1                 | 241 (17.8 %)          | 122 (50.6 %) |
| 2                 | 646 (47.6 %)          | 264 (40.9 %) |
| 3                 | 309 (22.8 %)          | 163 (52.8 %) |
| 4                 | 117 (8.6 %)           | 72 (61.5 %)  |
| 5+                | 45 (3.3 %)            | 28 (62.2 %)  |

# ECMO and age in adult Septic Shock



# Low survival for patients with SS and V-A ECMO

Taiwan 2001-2009






# Venoarterial Extracorporeal Membrane Oxygenation Support for Refractory Cardiovascular Dysfunction During Severe Bacterial Septic Shock\*

Nicolas Bréchet, MD, PhD<sup>1</sup>; Charles-Edouard Luyt, MD, PhD<sup>1</sup>; Matthieu Schmidt, MD<sup>1</sup>;

## Paris 2008-2011




71%

**Figure 1.** Outcomes of the 14 patients with refractory myocardial dysfunction during septic shock who received extracorporeal membrane oxygenation (ECMO) support

# Pneumonia as the principal cause of Septic Shock


| Patient | Age | Sex | Immunodeficiency   | Infection                          | Temperature at Admission (°C) |
|---------|-----|-----|--|------------------------------------|-------------------------------|
| 1       | 33  | M   | None   | CA pneumonia                       | 38.4                          |
| 2       | 62  | M   | None   | CA pneumonia                       | 37.7                          |
| 3       | 31  | F   | Chemotherapy for Ewing sarcoma   | Acute cholecystitis                | 38.5                          |
| 4       | 33  | F   | None   | Aspiration pneumonia               | 33.5                          |
| 5       | 48  | F   | HIV infection  | CA pneumonia                       | 39.7                          |
| 6       | 66  | M   | Hepatic transplantation  | Peritonitis after liver transplant | 35.8                          |
| 7       | 59  | M   | None   | CA pneumonia                       | 38.6                          |
| 8       | 52  | M   | None   | CA pneumonia                       | 40.1                          |
| 9       | 28  | F   | Corticosteroids for inflammatory bowel disease                               | CA pneumonia                       | 38.2                          |
| 10      | 35  | M   | None   | Aspiration pneumonia               | 38.9                          |
| 11      | 28  | F   | None   | Aspiration pneumonia               | 36                            |
| 12      | 52  | F   | Consolidation chemotherapy for acute myeloid leukemia                        | Nosocomial pneumonia               | 39.5                          |
| 13      | 57  | F   | Methotrexate and tumor necrosis factor inhibitors for ankylosing spondylitis | Pharyngitis                        | 40                            |
| 14      | 48  | M   | None   | CA pneumonia                       | 39.5                          |

# Septic Shock with depressed contractility!




# Cardiovascular response to sepsis

- Peripheral vasodilatation
- Intrinsic myocardial dysfunction, masked by the concomitant elevation in cardiac index
- Abnormal increase in left ventricular end-diastolic diameter in survivors



## MULTICENTER STUDY OF EARLY LACTATE CLEARANCE AS A DETERMINANT OF SURVIVAL IN PATIENTS WITH PRESUMED SEPSIS

Ryan C. Arnold,\* Nathan I. Shapiro,<sup>†</sup> Alan E. Jones,<sup>‡</sup> Christa Schorr,<sup>§</sup>




ARDS is frequent in septic patients  
ECMO fosters protective ventilation


Established role

VV-ECMO in Septic Shock related ARDS

# Hypercapnia induced by protective ventilation causes pulmonary hypertension and strain on RV



# Central role of RV in circulatory failure in ARDS





## Pulmonary vascular dysfunction in refractory acute respiratory distress syndrome before veno-venous extracorporeal membrane oxygenation

C. Lazzeri<sup>1</sup>, G. Cianchi<sup>2</sup>, M. Bonizzoli<sup>2</sup>, S. Batacchi<sup>2</sup>, P. Terenzi<sup>2</sup>, P. Bernardo<sup>1</sup>, S. Valente<sup>1</sup>, G. F. Gensini<sup>1,3</sup> and A. Peris<sup>2</sup>

---

|                     |                      |
|---------------------|----------------------|
| LV EF (%)           | 50 ± 9.5; 55 (20–58) |
| LV EF < 50%         | 6/21 (28.5%)         |
| SPAP (mmHg)         | 53.7 ± 7.9           |
| TAPSE (mm)          | 14.7 ± 4.5           |
| TAPSE < 16 mm (%)   | 10/21 (47.6%)        |
| Acute cor pulmonale | 2/21 (9.5%)          |


---

## Pulmonary vascular dysfunction in refractory acute respiratory distress syndrome before veno-venous extracorporeal membrane oxygenation

C. Lazzeri<sup>1</sup>, G. Cianchi<sup>2</sup>, M. Bonizzoli<sup>2</sup>, S. Batacchi<sup>2</sup>, P. Terenzi<sup>2</sup>, P. Bernardo<sup>1</sup>, S. Valente<sup>1</sup>, G. F. and A. Peris<sup>2</sup>

|   | Survivors<br><i>n</i> = 9 | Dead patients<br><i>n</i> = 12 | <i>P</i> values      |
|---|---------------------------|--------------------------------|----------------------|
| Age (years)                                       | 56.9 ± 9.6                | 50.3 ± 11.2                    | NS                   |
| Male gender %                                     | 6/9 (66.7%)               | 8/12 (66.7%)                   |                      |
| BMI   | 32.3 ± 10.8               | 29.2 ± 7.4                     | NS                   |
| SAPS II   | 56 ± 16                   | 44 ± 19                        | NS                   |
| Vasopressor infusion                              | 6/9 (66.7%)               | 7/12 (60%)                     | 0.03                 |
| Noradrenaline only                                | 6 (66.7%)                 | 2 (16.7%)                      |                      |
| Dobutamine only                                   | 0                         | 2 (16.7%)                      |                      |
| Noradrenalin and<br>dobutamine                    | 0                         | 3 (25%)                        |                      |
| Arterial blood gas                                |                           |                                |                      |
| PaO <sub>2</sub> /FiO <sub>2</sub>                | 79.7 ± 12                 | 85.9 ± 22                      | NS                   |
| PaO <sub>2</sub> (mmHg)                           | 73.3 ± 12                 | 91.1 ± 31.6                    | NS                   |
| PaCO <sub>2</sub> (mmHg)                          | 66.5 ± 15.9               | 55.4 ± 8.9                     | NS                   |
| ph  | 7.26 ± 0.06               | 7.35 ± 0.04                    | NS                   |
| Lactate (mmol/l)                                  | 1.6 ± 0.4                 | 2.5 ± 0.6                      | < 0.001              |
| ICU length (days)                                 | 27 ± 16                   | 36 ± 32                        | NS                   |
| MV ventilation<br>duration (days)                 | 24 ± 15                   | 35.3 ± 32                      | NS                   |
| ECMO duration<br>(days)                           | 22.6 ± 14                 | 20.5 ± 16                      | NS                   |
| Echocardiographic data                            |                           |                                |                      |
| LV < 50%  | 0 (0%)                    | 6(50%)                         | 0.04<br>(chi-square) |
| LV EF (%)   | 56.1 ± 2                  | 46.9 ± 11                      | 0.02                 |
| Pulmonary systolic<br>arterial pressure<br>(mmHg) | 47.7 ± 5.8                | 57 ± 6.7                       | 0.004                |
| TAPSE (mm)  | 16.9 ± 3.7                | 13 ± 4.5                       | 0.04                 |

# Lactates in ECMO survivals




Pulmonary & Cardiac failure



VA-ECMO

...but

# Pulmonary & Cardiac failure VA-ECMO



# Pulmonary & Cardiac failure

- V-VA ECMO...
- Central cannulation...



# Positive pre-ECLS cultures are a risk factor for infective complications


**Table 2** Multivariate analysis of risk factors for infection by age group

| Predictor                 | Neonates     |           |          |
|---------------------------|--------------|-----------|----------|
|                           | OR           | 95% CI    | <i>P</i> |
|                           | <i>Adult</i> |           |          |
| Positive pre-ECLS culture | 2.49         | 1.95-3.18 | <.001    |
| ECLS duration             | 1.09         | 1.07-1.11 | .002     |
| Age                       | 1.02         | 1.01-1.02 | <.001    |
| Type of complication      |              |           |          |
| Mechanical                | 1.54         | 1.22-1.95 | <.001    |
| Renal                     | 1.53         | 1.17-2    | .002     |
| Cardiovascular            | 1.77         | 1.25-2.51 | .001     |
| Metabolic                 | 2.27         | 1.79-2.88 | <.001    |
| Mode                      |              |           |          |
| VVDL                      | 0.11         | 0.01-0.88 | .038     |

# How do I proceed in a (septic) shocked patient...

Assess:

- RV function
- Pulmonary hypertension
- LV function





Do I consider to use ECMO in an adult patient with primary Septic Shock?

- No...(not yet)

Is shock a deterrent for ECMO?

- No...(not always)